659 related articles for article (PubMed ID: 28960184)
1. Fragile X syndrome.
Hagerman RJ; Berry-Kravis E; Hazlett HC; Bailey DB; Moine H; Kooy RF; Tassone F; Gantois I; Sonenberg N; Mandel JL; Hagerman PJ
Nat Rev Dis Primers; 2017 Sep; 3():17065. PubMed ID: 28960184
[TBL] [Abstract][Full Text] [Related]
2. Molecular Biomarkers in Fragile X Syndrome.
Zafarullah M; Tassone F
Brain Sci; 2019 Apr; 9(5):. PubMed ID: 31035599
[TBL] [Abstract][Full Text] [Related]
3. microRNAs and Fragile X Syndrome.
Lin SL
Adv Exp Med Biol; 2015; 888():107-21. PubMed ID: 26663181
[TBL] [Abstract][Full Text] [Related]
4. Fragile X syndrome: From protein function to therapy.
Bagni C; Oostra BA
Am J Med Genet A; 2013 Nov; 161A(11):2809-21. PubMed ID: 24115651
[TBL] [Abstract][Full Text] [Related]
5. Synaptic vesicle dynamic changes in a model of fragile X.
Broek JAC; Lin Z; de Gruiter HM; van 't Spijker H; Haasdijk ED; Cox D; Ozcan S; van Cappellen GWA; Houtsmuller AB; Willemsen R; de Zeeuw CI; Bahn S
Mol Autism; 2016; 7():17. PubMed ID: 26933487
[TBL] [Abstract][Full Text] [Related]
6. Disruption of GpI mGluR-Dependent Cav2.3 Translation in a Mouse Model of Fragile X Syndrome.
Gray EE; Murphy JG; Liu Y; Trang I; Tabor GT; Lin L; Hoffman DA
J Neurosci; 2019 Sep; 39(38):7453-7464. PubMed ID: 31350260
[TBL] [Abstract][Full Text] [Related]
7. Modeling fragile X syndrome in the Fmr1 knockout mouse.
Kazdoba TM; Leach PT; Silverman JL; Crawley JN
Intractable Rare Dis Res; 2014 Nov; 3(4):118-33. PubMed ID: 25606362
[TBL] [Abstract][Full Text] [Related]
8. STEP inhibition reverses behavioral, electrophysiologic, and synaptic abnormalities in Fmr1 KO mice.
Chatterjee M; Kurup PK; Lundbye CJ; Hugger Toft AK; Kwon J; Benedict J; Kamceva M; Banke TG; Lombroso PJ
Neuropharmacology; 2018 Jan; 128():43-53. PubMed ID: 28943283
[TBL] [Abstract][Full Text] [Related]
9. Clinical, molecular, and pharmacological aspects of FMR1 related disorders.
Pugin A; Faundes V; Santa María L; Curotto B; Aliaga S; Salas I; Soto P; Bravo P; Peña MI; Alliende MA
Neurologia; 2017 May; 32(4):241-252. PubMed ID: 25529181
[TBL] [Abstract][Full Text] [Related]
10. Fragile X syndrome.
Saldarriaga W; Tassone F; González-Teshima LY; Forero-Forero JV; Ayala-Zapata S; Hagerman R
Colomb Med (Cali); 2014; 45(4):190-8. PubMed ID: 25767309
[TBL] [Abstract][Full Text] [Related]
11. Fragile X: leading the way for targeted treatments in autism.
Wang LW; Berry-Kravis E; Hagerman RJ
Neurotherapeutics; 2010 Jul; 7(3):264-74. PubMed ID: 20643379
[TBL] [Abstract][Full Text] [Related]
12. Rare FMR1 gene mutations causing fragile X syndrome: A review.
Sitzmann AF; Hagelstrom RT; Tassone F; Hagerman RJ; Butler MG
Am J Med Genet A; 2018 Jan; 176(1):11-18. PubMed ID: 29178241
[TBL] [Abstract][Full Text] [Related]
13. Translational endpoints in fragile X syndrome.
de Esch CE; Zeidler S; Willemsen R
Neurosci Biobehav Rev; 2014 Oct; 46 Pt 2():256-69. PubMed ID: 24184744
[TBL] [Abstract][Full Text] [Related]
14. Fmr1 deficiency promotes age-dependent alterations in the cortical synaptic proteome.
Tang B; Wang T; Wan H; Han L; Qin X; Zhang Y; Wang J; Yu C; Berton F; Francesconi W; Yates JR; Vanderklish PW; Liao L
Proc Natl Acad Sci U S A; 2015 Aug; 112(34):E4697-706. PubMed ID: 26307763
[TBL] [Abstract][Full Text] [Related]
15. Fragile X syndrome and fragile X-associated tremor ataxia syndrome.
Hall DA; Berry-Kravis E
Handb Clin Neurol; 2018; 147():377-391. PubMed ID: 29325626
[TBL] [Abstract][Full Text] [Related]
16. Fragile X-like behaviors and abnormal cortical dendritic spines in cytoplasmic FMR1-interacting protein 2-mutant mice.
Han K; Chen H; Gennarino VA; Richman R; Lu HC; Zoghbi HY
Hum Mol Genet; 2015 Apr; 24(7):1813-23. PubMed ID: 25432536
[TBL] [Abstract][Full Text] [Related]
17. CGG-repeat dynamics and
Zhou Y; Kumari D; Sciascia N; Usdin K
Mol Autism; 2016; 7():42. PubMed ID: 27713816
[TBL] [Abstract][Full Text] [Related]
18. Human pluripotent stem cell models of Fragile X syndrome.
Bhattacharyya A; Zhao X
Mol Cell Neurosci; 2016 Jun; 73():43-51. PubMed ID: 26640241
[TBL] [Abstract][Full Text] [Related]
19. ICAM5 as a Novel Target for Treating Cognitive Impairment in Fragile X Syndrome.
Pei YP; Wang YY; Liu D; Lei HY; Yang ZH; Zhang ZW; Han M; Cheng K; Chen YS; Li JQ; Cheng GR; Xu L; Wu QM; McClintock SM; Yang Y; Zhang Y; Zeng Y
J Neurosci; 2020 Feb; 40(6):1355-1365. PubMed ID: 31882402
[TBL] [Abstract][Full Text] [Related]
20. Abnormal neuronal morphology and neurochemistry in the auditory brainstem of Fmr1 knockout rats.
Ruby K; Falvey K; Kulesza RJ
Neuroscience; 2015 Sep; 303():285-98. PubMed ID: 26166728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
